The FDA’s recent approvals of new Alzheimer’s drugs have been met with headlines filled with hope. Families, desperate for a lifeline, cling to the idea that these treatments could slow — or even stop — a disease that robs people of memory, independence, and identity. But as much as we want a medical breakthrough, the reality is sobering: these new drugs are not the long-awaited answer to Alzheimer’s.
1. They Offer Minimal Benefit at a High Cost
Clinical trials show these drugs can slow cognitive decline, but only slightly. In real-world terms, that might mean an extra few months of being able to remember a loved one’s name or manage daily tasks. That’s not nothing, but it’s far from a cure. Meanwhile, the cost can exceed tens of thousands of dollars annually, not counting the expenses for required imaging, monitoring, and infusions.
For many patients and families, the financial burden could outweigh the modest benefit, especially in a healthcare system where access to quality dementia care and caregiver support remains inconsistent.
2. They Come with Significant Risks
Many of these drugs target amyloid plaque buildup — long believed to be a hallmark of Alzheimer’s — using monoclonal antibodies. But in the process, they can cause serious side effects, including brain swelling and bleeding (known as ARIA, or amyloid-related imaging abnormalities). In some cases, these side effects can be fatal.
The need for frequent brain scans to monitor safety only adds to the complexity and stress of treatment, especially for older patients already dealing with multiple health conditions.
3. The Amyloid Hypothesis Isn’t the Whole Story
For decades, researchers have focused on amyloid plaques as the primary driver of Alzheimer’s. These new drugs are built on that theory, but evidence increasingly suggests that amyloid is only part of a much larger puzzle.
A complex web of factors, including tau tangles, vascular health, inflammation, and lifestyle influences Alzheimer’s. Even if amyloid is reduced, the disease can progress through other pathways, meaning the underlying decline may continue essentially unchanged.
Alzheimer’s disease is indeed associated with the buildup of amyloid plaques in the brain. These plaques are clumps of beta-amyloid, a protein fragment that, in healthy brains, is usually cleared away. In Alzheimer’s, these fragments accumulate between nerve cells, potentially disrupting cell-to-cell communication.
However, Alzheimer’s is also marked by another key feature: neurofibrillary tangles, which are twisted fibers of a protein called tau that form inside neurons. Both amyloid plaques and tau tangles are thought to contribute to the death of brain cells and the gradual loss of memory, thinking skills, and other cognitive functions.
In short:
- Yes → Amyloid plaque buildup is a hallmark of Alzheimer’s.
- But → tau tangles, inflammation, and other factors are also important in the disease process.
4. They Don’t Address Prevention or Quality of Life
A treatment that slightly slows decline but doesn’t stop it still leaves patients facing an inevitable loss of independence. The bigger missing piece? Prevention.
Lifestyle changes — such as improving cardiovascular health, staying physically active, maintaining social connections, and managing sleep — remain some of the most powerful tools we have for reducing dementia risk. These low-cost interventions don’t generate pharmaceutical profits, but they do generate real results over the long term.
Meanwhile, caregivers — the silent backbone of Alzheimer’s care — still struggle with burnout, financial strain, and a lack of resources. No drug can replace the need for comprehensive caregiver support and better dementia-friendly community infrastructure.
5. They Risk Distracting from Broader Solutions
High-profile drug launches can create a dangerous illusion that “the answer” is finally here. This can shift attention — and funding — away from other critical areas of research, including therapies that target tau pathology, inflammation, or neuroregeneration.
It can also delay investment in public health initiatives designed to reduce dementia rates and improve life for those already living with the disease.
The arrival of new Alzheimer’s drugs marks progress — but not a breakthrough. They are expensive, risky, and provide limited benefit. Without a cure, prevention, or better support systems, they can’t meet the real needs of patients and families facing this devastating disease.
Hope is essential, but so is honesty. We owe it to patients, caregivers, and the public to acknowledge that the fight against Alzheimer’s requires more than incremental drug advances. It requires a commitment to research that looks beyond amyloid, policies that expand access to care, and a cultural shift that values prevention as much as treatment.
Until then, these new drugs are a small piece of a much bigger puzzle — not the final picture we’ve been waiting for.

